Lorenzo Falchi, MD
Follicular lymphoma; Diffuse Large B-Cell Lymphoma; Marginal Zone Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia; Peripheral T-Cell Lymphoma; Burkitt Lymphoma; Clinical Trials Research; Immunotherapy; Novel Therapeutic Agents; Personalized Therapy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Falchi accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, University of Perugia
Internal Medicine - Yale-New Haven Hospital
Medical Oncology - University of Perugia, Italy; Leukemia - MD Anderson Cancer Center; Hematology/Oncology - NewYork-Presbyterian Hospital/Columbia University Medical Center
Internal Medicine; Hematology; Medical Oncology
As a board-certified medical oncologist and hematologist, I have been passionately dedicated to the study and treatment of blood diseases for well over a decade with a long-standing focus on the care of people with lymphoma. My practice benefits from years of experience that I gained while working at prestigious institutions.
At MSK, I am fortunate to be part of a multidisciplinary team of experts who share a deep commitment to developing effective therapies for all people with lymphoma. Our staff also provides an exceptional level of care and support for every one of our patients from the first point of contact, so that they are never alone during their time at MSK.
I am also deeply involved in conducting patient-centered research. At MSK, we offer one of the largest clinical trial portfolios for people with all types of lymphoma. I am especially interested in understanding how lymphoma interacts with the immune system. If we know how we can harness the immune system to fight lymphoma, we can develop new immunotherapies that can be used alone or in combination.
A lymphoma diagnosis can be overwhelming and terrifying. Most of my patients are naturally concerned about their future. I am convinced that the first step towards cure is defeating fear. That is why my priority is to clear up uncertainties by providing both information and education at every visit. I also believe that each person is unique, and my goal is to offer personalized care plans, while using the most effective and innovative treatments available today.
I am convinced that the first step towards cure is defeating fear. That is why my priority is to clear up uncertainties by providing both information and education at every visit.
Awards and Honors
- Best Research Fellow for the Leukemia Fellowship Program, MD Anderson Cancer Center (2013)
- Celgene Future Leaders in Hematology Award
- American Society of Hematology Abstract Achievement Award (2018)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Co-Investigated by Dr. Falchi
- A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
O’Connor OA, Falchi L, Lue J, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual J, Kim HA, Rada A, Atkins L, Khan K, Reilly A, Malanga M, Francescone M, Soderquist C, Park D, Cheng B, Risueno A, Menezes D, Shustov A, Sokol L, Scotto L. Targeting the Peripheral T-cell Lymphoma (PTCL) Epigenome with Oral 5-Azacytidine and Romidepsin Produces Marked Lineage Selective Activity in Patients with Chemotherapy Resistant Disease: A Multicenter Phase 1 Experience. Blood. Published ahead of print.
Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O’Connor OA. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol. 2016 Nov 30;9(1):132.
Vitale C,* Falchi L,* (equal contribution), ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O’Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory CLL: Correlation Between Responses and Immune Characteristics. Clin Cancer Res. 2016;22(10):2359-67.
Falchi L, Keating MJ, Marom EM, Truong M, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith S, Jain N, Estrov Z, O’Brien S, Lerner S, Ferrajoli A. Correlation between FDG/PET Findings, Histological Features, Clinical Characteristics and Survival in 332 Patients with Chronic Lymphocytic Leukemia. Blood. 2014;123:2783-90.
Visit PubMed for a full listing of Dr. Falchi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lorenzo Falchi discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.